Denne gang et fase 3 studie, der forsøger at vippe Arzerra af pinden i den eneste godkendte indikation; 3.line CLL:

A Phase 3 Study of Ibrutinib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RESONATE)
This study is not yet open for participant recruitment.
Verified April 2012 by Pharmacyclics

First Received on April 11, 2012. Last Updated on April 13, 2012